Die INITIATE-Studie: Beginn der Nikotinabhängigkeitsbehandlung für Raucher, die in Notaufnahmen aufgenommen wurden (INITIATE)
The INITIATE Study is a randomized controlled trial that is testing an intervention designed to increase long-term abstinence among tobacco smokers seen in emergency departments (ED) and other high-volume hospital and community ambulatory care settings. The intervention includes a behavioural incentive and tailored follow-up support on long-term smoking abstinence, health, healthcare utilization, and cost. Tobacco-related illnesses cost the healthcare system millions each year. Quitting smoking improves smoking-related outcomes, like the onset or management of heart disease, stroke, lung diseases, and several cancers. There are approximately 16 million visits to Canadian EDs each year; an estimated 3-4 million of these involve smokers. Effective quit smoking interventions exist, but are underutilized. Few hospital EDs, community healthcare centers, and other inpatient and outpatient clinics in Canada offer tobacco-use interventions. In order for clinicians to offer quit smoking support, interventions need to be simple given the realities of these high-volume environments. Considering that stopping smoking improves health outcomes, that tobacco-use is an important cause of preventable ED use, and the volume of smokers, Canadian EDs and other high-volume hospital and community ambulatory care settings are a missed opportunity in the initiation of quit smoking support. Our intervention has been designed to optimize uptake and smoking abstinence by including the most effective evidence-based behavioural and drug-related approaches, removing specific barriers and challenges that smokers face when trying to quit (e.g., affordability, low confidence and motivation), while packaging the intervention in a quick-to-initiate manner, making it ideal for fast-paced, complex environments.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Evyanne Wooding, R.Kin
- Telefonnummer: 17596 613-696-7000
- E-Mail: ewooding@ottawaheart.ca
Studieren Sie die Kontaktsicherung
- Name: Chantelle Masterson, BPhil
- Telefonnummer: 19157 613-696-7000
- E-Mail: cmasterson@ottawaheart.ca
Studienorte
-
-
Ontario
-
Ottawa, Ontario, Kanada
- Rekrutierung
- University of Ottawa Heart Institute
-
Kontakt:
- Dr. Kerri-Anne Mullen
- Telefonnummer: 613-696-7000 ext.19095
- E-Mail: KMullen@ottawaheart.ca
-
Ottawa, Ontario, Kanada
- Rekrutierung
- Civic Hospital
-
Kontakt:
- Dr. Venkatesh Thiruganasambandamoorthy
- Telefonnummer: 6137985555,17023
- E-Mail: vthirug@toh.ca
-
Ottawa, Ontario, Kanada
- Rekrutierung
- General Hospital
-
Kontakt:
- Dr. Venkatesh Thiruganasambandamoorthy
- Telefonnummer: 6137985555,17023
- E-Mail: vthirug@toh.ca
-
Ottawa, Ontario, Kanada
- Rekrutierung
- Riverside Hospital
-
Kontakt:
- Dr. Venkatesh Thiruganasambandamoorthy
- Telefonnummer: 6137985555,17023
- E-Mail: vthirug@toh.ca
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Current daily smoker (smokes ≥ 5 cigarettes per day);
- ≥ 18 years of age (the age of majority in Ontario);
- For ED sites only, assigned a CTAS level of 2-5 (emergent to non-urgent);
- Able to read and understand English or French;
- Resides in Ontario and eligible for Ontario Health Insurance Plan (to permit linkage with administrative data housed at the Institute for Clinical Evaluative Sciences [ICES]);
- Available and willing to participate in follow-up assessments over the next 12 months;
- Has access to a telephone or computer;
- Able to provide informed consent
Exclusion Criteria:
- Currently participating in this or another smoking cessation study;
- For ED sites only, assigned a CTAS level of 1 (resuscitation - the most seriously ill patients with highest likelihood of hospital admission) or in psychiatric emergency unit;
- Pregnant, planning to become pregnant over the next year, or breastfeeding;
- Has morbid illness which will prevent completion of 26-week follow-up (e.g., receiving palliative care);
- In the opinion of the attending physician, manifests acute physical and/or psychiatric illness or has cognitive impairment that would preclude participation in/benefit from the intervention.
- Scheduled for a known elected surgery, procedure, or future hospitalization during the study period.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Quit Card Intervention (QCI)
Study intervention group. |
The intervention is comprised of a behavioural incentive in the form of a gift card as well as tailored smoking cessation counseling. Eligible consenting smokers randomized to the QCI group will receive: a "Quit Card" (a gift card worth $300 that can be used to buy nicotine replacement therapies at any pharmacy); self-help information; and, enrollment in six months of telephone follow-up support tailored by treatment goal with a Nicotine Addiction Treatment Specialist. |
|
Kein Eingriff: Usual Care (UC)
Study control group. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Smoking Abstinence
Zeitfenster: 26 weeks (6 months) after study enrollment
|
Smoking abstinence at 26 weeks, biochemically verified using an expired air carbon monoxide (CO) test |
26 weeks (6 months) after study enrollment
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Prolonged Abstinence
Zeitfenster: 4, 26, and 52 weeks after study enrollment
|
Prolonged (since last time point) smoking abstinence, at 4, 26, and 52 weeks |
4, 26, and 52 weeks after study enrollment
|
|
Point Prevalence Abstinence
Zeitfenster: 4, and 52 weeks after study enrollment
|
Point prevalence smoking abstinence, at 4, and 52 weeks |
4, and 52 weeks after study enrollment
|
|
Smoking Reduction
Zeitfenster: 4, 26, and 52 weeks after study enrollment
|
Smoking reduction (i.e., change in number of daily cigarettes), at 4, 26, and 52 weeks |
4, 26, and 52 weeks after study enrollment
|
|
Number of Quit Attempts
Zeitfenster: 4, 26, and 52 weeks after study enrollment
|
Number of quit attempts since study entry, at 4, 26, and 52 weeks |
4, 26, and 52 weeks after study enrollment
|
|
Cessation Medication and/or E-cigarette Use
Zeitfenster: 4, 26, and 52 weeks after study enrollment
|
Use of smoking cessation medication and/or e-cigarette, at 4, 26, and 52 weeks |
4, 26, and 52 weeks after study enrollment
|
|
Use of Behavioural Supports
Zeitfenster: 4, 26, and 52 weeks after study enrollment
|
Use of behavioural supports (e.g., counseling, quit lines), at 4, 26, and 52 weeks |
4, 26, and 52 weeks after study enrollment
|
|
Health-Related Quality of Life
Zeitfenster: 52 weeks after study enrollment
|
Health-related quality of life (HR-QoL), at 52 weeks. This will be measured using the Hospital Anxiety and Depression Scale (HADS), designed to identify and measure the levels of anxiety and depression among individuals in non-psychiatric hospital settings, and the Health Questionnaire Assessment (EQ-5D-5L), using five graded severity levels to summarize perceived health across five foundational dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. |
52 weeks after study enrollment
|
|
Health Services Outcomes - ED visits
Zeitfenster: 4, 26, and 52 weeks after study enrollment
|
Number of all-cause and smoking-related (e.g., vascular, respiratory, cancer-related) visits to ED at 4, 26, and 52 weeks |
4, 26, and 52 weeks after study enrollment
|
|
Health Services Outcomes - Hospital Admissions
Zeitfenster: 4, 26, and 52 weeks after study enrollment
|
Number of all-cause and smoking-related (e.g., vascular, respiratory, cancer-related) admissions to hospital at 4, 26, and 52 weeks |
4, 26, and 52 weeks after study enrollment
|
|
Health Services Outcomes - Deaths
Zeitfenster: 4, 26, and 52 weeks after study enrollment
|
Number of all-cause and smoking-related (e.g., vascular, respiratory, cancer-related) deaths at 4, 26, and 52 weeks |
4, 26, and 52 weeks after study enrollment
|
|
Cost-Effectiveness Ratios
Zeitfenster: 52 weeks after study enrollment
|
Cost-effectiveness ratios related to health services at 52 weeks |
52 weeks after study enrollment
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Ermittler
Ermittler
- Hauptermittler: Kerri-Anne Mullen, PhD, Ottawa Heart Institute Research Corporation
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 20190485-01H
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .